



Institutional Biosafety Committee
Meeting Minutes

Date: 02/27/2026 Start time: 9:00am (ET) End time: 11:00am (ET)

Advarra IBC meetings are closed to the public to protect confidential and proprietary information as outlined in the Advarra IBC standard operating procedures.

Chair: Warren Rummage

Voting Members Present: Dan Eisenman (Committee Member), Scott Swindle (Committee Member), Darlene Ward (Committee Member), Nichole Tower (Committee Member), Alain Houmeidan (Committee Member), Jackie Lomeli (Committee Member), Paul Gulig (Committee Member)

No Community Members were present for this review. The Community Member that was assigned to this review was unable to attend the meeting. The committee voted unanimously in favor to conduct the review without a Community Member in attendance.

Other Persons Present: [REDACTED]

Conflict of Interest: The IBC Chair queried the IBC to identify any potential conflicts of interest and requested that any potential conflicts of interest be disclosed to the IBC. The IBC Chair then reminded the IBC that if any potential conflicts of interest were identified as the meeting progressed, disclosure would need to occur at that time. Identified potential conflict of interest: Yes No

Study Summary Information for Minutes			
Protocol #	[REDACTED]	IBC Study Submission ID #	PROTO202500051
Study Title	A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of [REDACTED] in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration [REDACTED]		
Agent	Adeno-Associated Virus (AAV)		
Agent Characteristics	Replication deficient vector; Risk Group 1		
rDNA Category	III-C-1		
Description of Recombinant Nucleic Acid Sources	• [REDACTED]		

	<ul style="list-style-type: none"> • [REDACTED] 		
Description of Genetically Modified Microbes or Vectors	<ul style="list-style-type: none"> • Replication-deficient Adeno-associated virus (AAV) 		
Description of Transgene Expression	<ul style="list-style-type: none"> • [REDACTED] • [REDACTED] 		
Risk Assessment of Procedures	<ul style="list-style-type: none"> • Preparation of Dose <ul style="list-style-type: none"> ○ Sharps Safety ○ Standard Precautions • Administered Injection into the Eye <ul style="list-style-type: none"> ○ Sharps Safety ○ Standard Precautions • Dispose of all materials as biohazardous waste 		
Site Information			
Site Name	Retina Vitreous Surgeons of CNY, PC - Liverpool, NY	IBC Site Submission ID #	SAF202600035
PI Name	Jamin Brown, MD		
Site Biosafety Level	BSL2		
Staff Training Verified by PI Signed SOP	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No	
Motions, Votes, and Committee's Decision			
Motion: Approve			
Conditions: N/A			
Motion	First: [REDACTED]	Second: [REDACTED]	

Votes	For: 8	Against: 0	Recused: 0	Absent: 0	Abstained: 0
--------------	---------------	-------------------	-------------------	------------------	---------------------

Chair Signature
Approved by Chair: Name: Warren Rummage Date: 2026/03/02